Breast Cancer Gene Patent Resolved

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

WASHINGTON--The National Institutes of Health, University of Utah, and Myriad Genetics, Inc. have resolved issues involving patenting of the BRCA1 breast cancer gene by agreeing that scientists from all three institutions should be named as joint inventors in current patent applications. The agreement also ensures that exclusive, worldwide commercial rights are retained by Myriad and its licensees, Eli Lilly and Company and Hybritech Incorporated.

WASHINGTON--The National Institutes of Health, University of Utah,and Myriad Genetics, Inc. have resolved issues involving patentingof the BRCA1 breast cancer gene by agreeing that scientists fromall three institutions should be named as joint inventors in currentpatent applications. The agreement also ensures that exclusive,worldwide commercial rights are retained by Myriad and its licensees,Eli Lilly and Company and Hybritech Incorporated.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content